WO2008092405A1 - Method for synthesizing 1,2,3-tri-o-acetyl-5-deoxy-d-ribose - Google Patents

Method for synthesizing 1,2,3-tri-o-acetyl-5-deoxy-d-ribose Download PDF

Info

Publication number
WO2008092405A1
WO2008092405A1 PCT/CN2008/070190 CN2008070190W WO2008092405A1 WO 2008092405 A1 WO2008092405 A1 WO 2008092405A1 CN 2008070190 W CN2008070190 W CN 2008070190W WO 2008092405 A1 WO2008092405 A1 WO 2008092405A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
deoxyinosine
acetyl
inosine
deoxy
Prior art date
Application number
PCT/CN2008/070190
Other languages
French (fr)
Chinese (zh)
Inventor
Chengju Wang
Donglin Tang
Original Assignee
Donglin Tang
Chengju Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Donglin Tang, Chengju Wang filed Critical Donglin Tang
Publication of WO2008092405A1 publication Critical patent/WO2008092405A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06Fatty acids

Definitions

  • the invention relates to a preparation method of a pharmaceutical intermediate, in particular to a method for synthesizing an antitumor nucleoside drug intermediate 5-deoxy-D-ribose, in particular to 1,2,3-tri-O-acetyl A method for the synthesis of keto-5-deoxy-D-ribose intermediates. Background technique
  • 1, 2, 3-Tri-O-acetyl-5-deoxy-D-ribose is an intermediate for the synthesis of nucleoside drugs.
  • the synthesis method of the intermediate is mainly prepared by reacting five-carbon sugar or penta-deoxyribose as raw materials with acetic anhydride, and the raw materials thereof are difficult to obtain, and the intermediates prepared are high in cost. Summary of the invention
  • the technical problem to be solved is to seek a new synthetic starting material for the intermediate and a novel synthesis method thereof .
  • the present invention provides a method for synthesizing 5-deoxy-D-ribose represented by the formula I, characterized in that the inosine of the formula V is used as a raw material, and the compound of the formula I is obtained by the following steps:
  • Ri, R 2 and R 3 are the same or different and each independently is a hydroxy protecting group.
  • hydroxy protecting groups are well known to the skilled person in the field of organic chemistry, and examples thereof can be found in Greene & Wuts, "protective groups in organic synthesis", John Wiley & Sons, NY (1991).
  • R 2, R 3 are the same, are an acetyl group.
  • the inosine is halogenated to form a 5-substituted-5-deoxyinosine of the formula IV, and then hydrogenated to obtain a 5-deoxy muscle of the formula III.
  • X is a halogen atom such as bromine, iodine or the like, and among them, iodine is preferred.
  • Ri, R 2 and R 3 are the same or different and are each independently a hydroxy protecting group.
  • Hydroxy protecting groups which are well known to the skilled person in the field of organic chemistry, are described, for example, in Greene & Wuts, "protective groups in organic synthesis", John Wiley & Sons, NY (1991). In the present invention, it is preferred that R 2 and R 3 are the same and both are acetyl groups.
  • 1,2,3-tri-O-acetyl-5-deoxy-D represented by formula la is obtained by the method comprising the following steps, using inosine of the formula V as a raw material -ribose:
  • inosine of the formula V as a raw material -ribose:
  • 5-inodo-5-deoxyinosine of formula IVa is prepared by reacting inosine of formula V with iodine in an organic solvent.
  • the inosine of the formula V is in the fluorene, in the presence of an imidazole and a triphenylphosphine catalyst, at 80-120 ° C with iodine 5-Iodo-5-deoxyinosine of formula IVa is formed by reacting for 4-6 hours, wherein the mass ratio of inosine to imidazole, inosine and triphenylphosphine, and inosine and iodine are 1: 0.8-1.4, 1: 1 ⁇ 1.4 and 1: 0.9 ⁇ 1.4.
  • step (2) 5-iodo-5-deoxyinosine of the formula IVa is reacted with hydrogen in the presence of triethylamine in methanol with nickel as a catalyst.
  • 5-Deoxyinosine of formula III is produced wherein the amount of nickel is from 30 to 50% of 5-iodo-5-deoxyinosine of formula IVa.
  • inosine is reacted with iodine added in batches at 80-120 ° C for 4-6 hours in the presence of the catalyst imidazole and triphenylphosphine, then methanol is neutralized, and finally 5-10% (quality) Percentage, the same as) sulfite saturated brine solution (that is, adding NaCl to saturation in 5 ⁇ 10% sulfurous acid solution), stirring for 20 to 30 minutes, standing, freezing and crystallization, filtering, and filtering the residue with toluene to obtain a white solid.
  • sulfite saturated brine solution that is, adding NaCl to saturation in 5 ⁇ 10% sulfurous acid solution
  • the product 5-iodo-5-deoxyinosine, the mass ratio of inosine to imidazole, triphenylphosphine and iodine was 1: 0.8 - 1.4, 1: 1 ⁇ 1.4 and 1: 0.9 - 1.4, respectively.
  • the intermediate 2, 3-di-O-acetyl-5-deoxyinosine is added to a mixed solution of acetic anhydride and acetic acid, heated and heated under the action of a strong acidic cationic resin for 4-8 hours, cooled and filtered and separated.
  • the filtrate was concentrated to dryness, and an aqueous methanol solution (methanol to water volume ratio of 3:1) was added. After dissolution, the crystals were allowed to stand for crystallization and separation to obtain white crystals, i.e., the target product 1, 2, 3-tri-O-acetyl-5-deoxy- D-ribose.
  • the synthetic route is as follows:
  • the synthesis method of the present invention is to first convert a hydroxymethylene group at the 5-position of the glycosidic group to a methyl group to obtain a 5-deoxygen muscle. Glycosides. The hydroxy group on the two sides of the glycosidic group 2, 3 is then acetylated to give 2,3-di-0-acetyl-5-deoxyinosine. Finally, the deglycosyl group is simultaneously acetylated at the 1-position to give the target product.

Abstract

The invention discloses a method for synthesizing 1,2,3-tri-O-acetyl-5-deoxy-D -ribose, an intermediate of nucleotide compounds: using inosine as starting material and firstly reacting inosine with iodine in an organic solvent to obtain 5-iodo-5-deoxyinosine; then using Ni as a catalyst, introducing hydrogen in liquid phase to obtain 5-deoxyinosine; reacting the obtained 5-deoxyinosine with acetic anhydride in an organic solvent to obtain 2,3-di-O-acyl-5-deoxyinosine; and lastly treating the obtained 2,3-di-O-acyl-5-deoxyinosine with a strong-acid cation exchange resin in acetic anhydride-acetic acid mixed solvent to break bond and remove glycoside to obtain the target product 1,2,3-tri-O-acetyl-5-deoxy-D-ribose. The method has the advantages of raw material easy to get and cheap, operation and control simple, and yield of every unit reaction high; and total yield of the method is up to 61.5%.

Description

1, 2, 3-三 -0-乙酰基 -5-脱氧 -D-核糖合成方法 技术领域  1, 2, 3-tri-O-acetyl-5-deoxy-D-ribose synthesis method
本发明涉及一种医药中间体的制备方法, 具体地说, 涉及抗肿瘤核苷类 药物中间体 5-脱氧 -D-核糖的合成方法,尤其是涉及 1,2, 3-三 -0-乙酰基 -5- 脱氧 -D-核糖中间体的合成方法。 背景技术  The invention relates to a preparation method of a pharmaceutical intermediate, in particular to a method for synthesizing an antitumor nucleoside drug intermediate 5-deoxy-D-ribose, in particular to 1,2,3-tri-O-acetyl A method for the synthesis of keto-5-deoxy-D-ribose intermediates. Background technique
1, 2, 3-三 -0-乙酰基 -5-脱氧 -D-核糖是合成核苷类药物的中间体。 目 前该中间体的合成方法, 主要是以五碳糖或者五脱氧核糖为原料, 与醋酐 反应制备的, 其原料难求, 制备的中间体成本高。 发明内容  1, 2, 3-Tri-O-acetyl-5-deoxy-D-ribose is an intermediate for the synthesis of nucleoside drugs. At present, the synthesis method of the intermediate is mainly prepared by reacting five-carbon sugar or penta-deoxyribose as raw materials with acetic anhydride, and the raw materials thereof are difficult to obtain, and the intermediates prepared are high in cost. Summary of the invention
-D-核糖, 尤其是 1, 2, 3-三 -0-乙酰基 -5-脱氧 -D-核糖, 所要解决的技术 问题是寻求该中间体新的合成起始原料及其新的合成方法。 -D-ribose, especially 1,2,3-tri-O-acetyl-5-deoxy-D-ribose, the technical problem to be solved is to seek a new synthetic starting material for the intermediate and a novel synthesis method thereof .
本发明技术方案如下:  The technical scheme of the present invention is as follows:
本发明提供一种式 I所示 5-脱氧 -D-核糖的合成方法,其特征在于由式 V的肌苷为原料, 经如下步骤得到式 I化合物:  The present invention provides a method for synthesizing 5-deoxy-D-ribose represented by the formula I, characterized in that the inosine of the formula V is used as a raw material, and the compound of the formula I is obtained by the following steps:
(1)肌苷的糖 5位上的羟亚甲基转化为甲基, 制得式 III的 5-脱氧肌 苷  (1) The hydroxymethylene group at the 5-position of the inosine is converted to a methyl group to prepare 5-deoxyinosine of the formula III.
Figure imgf000003_0001
Figure imgf000003_0001
III ( 2 ) 5_脱氧肌苷经羟 糖苷基, 制得式 I的 5-脱氧 -D-核糖 III (2) 5 -deoxyinosine via hydroxyglycoside to produce 5-deoxy-D-ribose of formula I
Figure imgf000004_0001
Figure imgf000004_0001
III 其中, Ri、 R2、 R3相同或者不同, 各自独立地为羟基保护基。 其中, 羟 基保护基,是有机化学领域中, 为技术人员所熟知的,其实例可参见 Greene & Wuts, "protective groups in organic synthesis", John Wi ley & Sons, NY (1991)。 其中本发明优选 R2、 R3相同, 均为乙酰基。 III wherein Ri, R 2 and R 3 are the same or different and each independently is a hydroxy protecting group. Among them, hydroxy protecting groups are well known to the skilled person in the field of organic chemistry, and examples thereof can be found in Greene & Wuts, "protective groups in organic synthesis", John Wiley & Sons, NY (1991). Preferably the present invention wherein R 2, R 3 are the same, are an acetyl group.
上述所述的方法, 其中, 所述的步骤(1 ) 中, 肌苷经卤代反应形成式 IV的 5- 代 -5-脱氧肌苷, 再经氢化反应制得式 III的 5-脱氧肌苷  In the above-mentioned method, wherein in the step (1), the inosine is halogenated to form a 5-substituted-5-deoxyinosine of the formula IV, and then hydrogenated to obtain a 5-deoxy muscle of the formula III. Glycosides
Figure imgf000004_0002
其中, 所述的 X为卤原子, 例如溴、 碘等, 其中优选为碘。
Figure imgf000004_0002
Wherein X is a halogen atom such as bromine, iodine or the like, and among them, iodine is preferred.
上述所述的方法, 其中, 所述的步骤(2 ) 中, 5-脱氧肌苷糖上的羟基 经保护后形成式 II 的 5-脱氧肌苷, 再脱糖苷基和保护羟基, 制得式 I 的 The method according to the above, wherein, in the step (2), the hydroxyl group on the 5-deoxyinosine saccharide is protected to form 5-deoxyinosine of the formula II, then the deglycosyl group and the hydroxy group are protected. I
5-脱氧 -D-核糖 5-deoxy-D-ribose
Figure imgf000004_0003
其中, Ri、 R2、 R3相同或者不同, 各自独立地为羟基保护基。 羟基保护 基, 是有机化学领域中, 为技术人员所熟知的, 其实例例如可参见 Greene & Wuts , "protective groups in organic synthesis", John Wiley & Sons, NY (1991)。 本发明中, 优选 R2、 R3相同, 均为乙酰基。
Figure imgf000004_0003
Wherein Ri, R 2 and R 3 are the same or different and are each independently a hydroxy protecting group. Hydroxy protecting groups, which are well known to the skilled person in the field of organic chemistry, are described, for example, in Greene & Wuts, "protective groups in organic synthesis", John Wiley & Sons, NY (1991). In the present invention, it is preferred that R 2 and R 3 are the same and both are acetyl groups.
作为本发明一具体实施方案, 其中, 由式 V 的肌苷为原料, 经包含如 下步骤的方法制得式 la所示的 1, 2, 3-三 -0-乙酰基 -5-脱氧 -D-核糖: ( 1 )在有机溶剂中式 V的肌苷与碘反应制得式 IVa的 5-碘代 -5-脱氧肌苷  As a specific embodiment of the present invention, wherein 1,2,3-tri-O-acetyl-5-deoxy-D represented by formula la is obtained by the method comprising the following steps, using inosine of the formula V as a raw material -ribose: (1) 5-inodo-5-deoxyinosine of formula IVa is prepared by reacting inosine of formula V with iodine in an organic solvent.
Figure imgf000005_0001
Figure imgf000005_0001
V IVa  V IVa
(2) 式 IVa的 5-碘代 -5-脱
Figure imgf000005_0002
(2) 5-iodo-5- off of formula IVa
Figure imgf000005_0002
制得式 III的 5-脱氧肌苷 5-deoxyinosine of formula III
Figure imgf000005_0003
Figure imgf000005_0003
IVa III
Figure imgf000005_0004
其中, Ac表示乙酰基;
IVa III
Figure imgf000005_0004
Wherein Ac represents an acetyl group;
( 4 )在醋酐和醋酸的混合溶剂中,在强酸性阳离子树脂作用下式 Ila的 2, 3- 二 -0-乙酰基 -5-脱氧肌苷断键脱糖苷制得式 la 的 1,2, 3-三 -0-乙酰基 -5- 脱氧 -D-核糖  (4) In the mixed solvent of acetic anhydride and acetic acid, 2, 3-di-0-acetyl-5-deoxyinosine of the formula Ila is deactivated by a strong acidic cationic resin to obtain 1, 2, 3-Tri-0-acetyl-5-deoxy-D-ribose
Figure imgf000006_0001
Figure imgf000006_0001
Ila la 其中, Ac表示乙酰基。  Ila la wherein Ac represents an acetyl group.
其中, 上述所述的方法, 其中所述的步骤(1 )中, 式 V的肌苷是在丽 F 中, 在咪唑和三苯基膦催化剂存在下, 于 80-120°C条件下与碘反应 4~6小 时生成式 IVa的 5-碘代 -5-脱氧肌苷, 其中, 肌苷与咪唑、 肌苷与三苯基膦 和肌苷与碘的质量比依次为 1: 0.8-1.4, 1: 1 ~ 1.4和 1: 0.9~1.4。  Wherein the method described above, wherein in the step (1), the inosine of the formula V is in the fluorene, in the presence of an imidazole and a triphenylphosphine catalyst, at 80-120 ° C with iodine 5-Iodo-5-deoxyinosine of formula IVa is formed by reacting for 4-6 hours, wherein the mass ratio of inosine to imidazole, inosine and triphenylphosphine, and inosine and iodine are 1: 0.8-1.4, 1: 1 ~ 1.4 and 1: 0.9~1.4.
其中, 上述所述的方法, 其中所述的步骤(2)中, 式 IVa的 5-碘代 -5- 脱氧肌苷在甲醇中, 以镍为催化剂, 在三乙胺存在条件下与氢气反应生成 式 III的 5-脱氧肌苷,其中,镍用量为式 IVa的 5-碘代 -5-脱氧肌苷的 30 ~ 50%。  Wherein, in the above-mentioned method, in the step (2), 5-iodo-5-deoxyinosine of the formula IVa is reacted with hydrogen in the presence of triethylamine in methanol with nickel as a catalyst. 5-Deoxyinosine of formula III is produced wherein the amount of nickel is from 30 to 50% of 5-iodo-5-deoxyinosine of formula IVa.
其中, 上述所述的方法, 其中所述的步骤(3) 中, 式 III的 5-脱氧肌 苷是在二氯甲烷中,在三乙胺存在条件下与醋酐于 40 ~ 50°C反应 1 ~ 3小时 生成式 Ila的 2, 3-二 -0-乙酰基 -5-脱氧肌苷。  Wherein, in the above-mentioned method, wherein in the step (3), the 5-deoxyinosine of the formula III is reacted with acetic anhydride at 40 to 50 ° C in the presence of triethylamine in dichloromethane. 2, 3-Di-0-acetyl-5-deoxyinosine of the formula Ila is formed in 1 to 3 hours.
其中, 上述所述的方法, 其中所述的步骤(4)中, 式 Ila的 2, 3-二 -0- 乙酰基 -5-脱氧肌苷加到醋酐和醋酸的混合溶剂中, 再加入强酸性阳离子树 脂加热回流 4 ~8小时生成式 la的 1, 2, 3-三 -0-乙酰基 -5 -脱氧 _D-核糖。 更具体地, 其合成过程如下: Wherein, in the above-mentioned method, wherein in the step (4), 2,3-di-0-acetyl-5-deoxyinosine of the formula Ila is added to a mixed solvent of acetic anhydride and acetic acid, and then added The strongly acidic cationic resin is heated under reflux for 4-8 hours to form 1,2,3-tri-O-acetyl-5-deoxy-D-ribose of the formula la. More specifically, the synthesis process is as follows:
1、 碘化制备中间产物 5-碘代 -5-脱氧肌苷 1. Preparation of intermediates by iodination 5-iodo-5-deoxyinosine
以 DMF为溶剂, 在催化剂咪唑和三苯基膦存在条件下于 80~ 120°C时肌 苷与分批量加入的碘反应 4 ~ 6小时, 然后甲醇中和, 最后加入 5 ~ 10% (质 量百分比, 下同)亚硫酸饱和盐水溶液(即在 5 ~ 10%亚硫酸溶液中加 NaCl 至饱和), 搅拌 20~ 30分钟, 静置, 冷冻结晶、 过滤, 滤渣用甲苯漂洗得 到白色固体即中间产物 5-碘代- 5-脱氧肌苷, 肌苷与咪唑、 三苯基膦和碘的 质量比依次为 1: 0.8 - 1.4、 1: 1 ~ 1.4和 1: 0.9 - 1.4。  Using DMF as solvent, inosine is reacted with iodine added in batches at 80-120 ° C for 4-6 hours in the presence of the catalyst imidazole and triphenylphosphine, then methanol is neutralized, and finally 5-10% (quality) Percentage, the same as) sulfite saturated brine solution (that is, adding NaCl to saturation in 5 ~ 10% sulfurous acid solution), stirring for 20 to 30 minutes, standing, freezing and crystallization, filtering, and filtering the residue with toluene to obtain a white solid. The product 5-iodo-5-deoxyinosine, the mass ratio of inosine to imidazole, triphenylphosphine and iodine was 1: 0.8 - 1.4, 1: 1 ~ 1.4 and 1: 0.9 - 1.4, respectively.
2、 氢化制备中间产物 5-脱氧肌苷  2. Hydrogenation to prepare intermediates 5-deoxyinosine
以甲醇为溶剂和镍为催化剂,在室温和三乙胺存在条件下通入氢气与中 间产物 5-碘代 -5-脱氧肌苷反应至终点, 然后过滤, 滤液浓缩, 冷却结晶、 分离,得到白色晶体即中间产物 5-脱氧肌苷,镍用量为中间产物 5-碘代 -5- 脱氧肌苷的 30~ 50%。  Using methanol as solvent and nickel as catalyst, hydrogen and intermediate 5-iodo-5-deoxyinosine were reacted to the end point in the presence of room temperature and triethylamine, then filtered, and the filtrate was concentrated, cooled and crystallized, and separated. The white crystal is the intermediate product 5-deoxyinosine, and the amount of nickel is 30 to 50% of the intermediate 5-iodo-5-deoxyinosine.
3、 酰基化制备中间产物 2, 3-二 -0-乙酰基 -5-脱氧肌苷  3. Preparation of an intermediate by acylation 2, 3-di-O-acetyl-5-deoxyinosine
以二氯乙烷为溶剂, 在三乙胺存在条件下中间产物 5-脱氧肌苷与醋酐 于 40~ 50°C反应 1 ~ 3 小时, 浓缩结晶、 分离, 得到白色粉末即中间产物 2, 3-二 -0-乙酰基 -5-脱氧肌苷。  Using dichloroethane as a solvent, the intermediate product 5-deoxyinosine and acetic anhydride are reacted at 40-50 ° C for 1 to 3 hours in the presence of triethylamine, concentrated and crystallized, and separated to obtain a white powder, intermediate product 2, 3-Di-0-acetyl-5-deoxyinosine.
4、 由中间产物 2, 3-二 -0-乙酰基 -5-脱氧肌苷制备目标产物  4. Preparation of the target product from the intermediate product 2, 3-di-O-acetyl-5-deoxyinosine
将中间体 2, 3-二 -0-乙酰基 -5-脱氧肌苷加入醋酐和醋酸的混合溶液 中, 在强酸性阳离子树脂的作用下加热回热 4 ~ 8小时, 冷却后过滤分离, 浓缩滤液至干, 加甲醇水溶液 (甲醇与水体积比 3: 1 ), 溶解后静置结晶、 分离, 得到白色晶体即目标产物 1, 2, 3-三 -0-乙酰基 -5-脱氧 -D-核糖。  The intermediate 2, 3-di-O-acetyl-5-deoxyinosine is added to a mixed solution of acetic anhydride and acetic acid, heated and heated under the action of a strong acidic cationic resin for 4-8 hours, cooled and filtered and separated. The filtrate was concentrated to dryness, and an aqueous methanol solution (methanol to water volume ratio of 3:1) was added. After dissolution, the crystals were allowed to stand for crystallization and separation to obtain white crystals, i.e., the target product 1, 2, 3-tri-O-acetyl-5-deoxy- D-ribose.
其合成路线如下:  The synthetic route is as follows:
Figure imgf000007_0001
肌苷
Figure imgf000008_0001
Figure imgf000007_0001
Inosine
Figure imgf000008_0001
2, 3-二 -O-乙酰基 -5-脱氧肌苷  2, 3-di-O-acetyl-5-deoxyinosine
醋酐 /树脂 Acetic anhydride / resin
Figure imgf000008_0002
Figure imgf000008_0002
1, 2, 3-三 -O-乙酰基 -5-脱氧 -D-核糖 本发明合成方法, 其思路是首先将糖苷基 5位上的羟亚甲基转化为甲 基, 得到 5-脱氧肌苷。 然后将糖苷基 2 , 3两位上的羟基乙酰基化, 得到 2 , 3-二 -0-乙酰基 -5-脱氧肌苷。 最后脱糖苷基同时在 1 位上乙酰基化得到目 标产物。 与现有技术相比, 主要区别在于以肌苷为起始原料, 其原料易得 且价格便宜, 操作、 控制简单, 各单元反应收率高, 总收率达 61. 5%。 产物 熔点 66 ~ 67 °C。 具体实施方式 下面通过实施例进一步说明本发明。所述的实施例不应被理解为是对本 发明内容或主旨的限定。 1, 2, 3-Tri-O-acetyl-5-deoxy-D-ribose The synthesis method of the present invention is to first convert a hydroxymethylene group at the 5-position of the glycosidic group to a methyl group to obtain a 5-deoxygen muscle. Glycosides. The hydroxy group on the two sides of the glycosidic group 2, 3 is then acetylated to give 2,3-di-0-acetyl-5-deoxyinosine. Finally, the deglycosyl group is simultaneously acetylated at the 1-position to give the target product. 5%。 Compared with the prior art, the main difference is that the inosine as a starting material, the raw material is easy to obtain and the price is low, the operation and control are simple, the reaction yield of each unit is high, the total yield is 61.5%. The product has a melting point of 66 to 67 °C. BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be further described by way of examples. The described embodiments are not to be construed as limiting the scope or spirit of the invention.
实施例 1: 中间产物 5-碘代 -5-脱氧肌苷( IVa) 的制备 Example 1: Preparation of intermediate 5-iodo-5-deoxyinosine (IVa)
50g (0.187mol )肌苷与催化剂咪唑和三苯基膦加入 DMF中搅拌, 其中 咪唑加入量应 45g ~ 65g,三苯基膦加入量为 55g ~ 65g,DMF加入量为 75ml ~ 150ml, 油浴加热, 反应温度控制在 80°C ~120°C之间, 将碘分三批加入, 碘加入量为 50g~65g, 反应时间 4~6小时, TCL检测反应结束加 75ml 甲 醇中和, 搅拌半小时, 加入 100ml ~ 400ml 8%亚硫酸饱和盐水溶液, 搅拌半 小时, 放入冰箱冷冻过夜, 结晶, 过滤, 滤渣用甲苯洗 3~ 6次, 得白色固 体(IVa) 64g, 收率在 90%。 高效液相检测含量大于 98%。 实施例 2: 中间产物 5-脱氧肌苷(III) 的制备  50g (0.187mol) of inosine and catalyst imidazole and triphenylphosphine were added to DMF and stirred, wherein the amount of imidazole should be 45g ~ 65g, the amount of triphenylphosphine added is 55g ~ 65g, the amount of DMF added is 75ml ~ 150ml, oil bath Heating, the reaction temperature is controlled between 80 ° C ~ 120 ° C, the iodine is added in three batches, the amount of iodine is 50g ~ 65g, the reaction time is 4 ~ 6 hours, TCL detection reaction is finished with 75ml methanol neutralization, stirring half Hour, add 100ml ~ 400ml 8% sulfuric acid saturated brine solution, stir for half an hour, put it in the refrigerator for freezing overnight, crystallize, filter, filter residue with toluene wash 3~6 times, get white solid (IVa) 64g, yield 90% . The HPLC detection content is greater than 98%. Example 2: Preparation of intermediate 5-deoxyinosine (III)
50g 5 -殃 _5_脱氧肌苷加入 250ml ~ 500ml 甲醇中, 加入 30ml ~ 55ml三 乙胺、 20g镍催化剂, 常温下通入氢气反应 12— 24小时左右, 经 TCL检测 原料点消失, 结束反应, 反应液过滤, 除去催化剂, 滤液浓缩至少量, 冷 却结晶, 过滤得白色晶体 30g, 收率 90%。 高效液相检测含量大于 98.5%。 实施例 3: 2、 3-二- 0-乙酰基 -5-脱氧-肌苷(Ila) 的制备  50g 5 -殃_5_deoxyinosine is added to 250ml ~ 500ml methanol, 30ml ~ 55ml triethylamine, 20g nickel catalyst is added, hydrogen reaction is carried out at room temperature for 12-24 hours, the raw material point disappears by TCL, and the reaction is terminated. The reaction solution was filtered, the catalyst was removed, and the filtrate was concentrated to a minimum amount. The crystals were cooled and filtered to yield white crystals (30 g). The HPLC detection content is greater than 98.5%. Example 3: Preparation of 2, 3-di-O-acetyl-5-deoxy-inosine (Ila)
50g ( 0.198 ) 5_脱氧肌苷加入 100ml二氯甲烷中, 加入 20ml ~ 55ml三 乙胺和 40~80ml醋酐在 40°C ~50°C左右反应 1 ~ 3小时, TCL检测, 反应 结束浓缩至少量结晶, 过滤得白色粉末 63.3g, 收率 95%。 高效液相检测含 量大于 98%。 实施例 4: 1, 2, 3-三- 0-乙酰基 -5-脱氧- D-核糖的制备  50g (0.198) 5_deoxyinosine is added to 100ml of dichloromethane, 20ml ~ 55ml of triethylamine and 40~80ml of acetic anhydride are added to react at 40 °C ~ 50 °C for 1-3 hours, TCL detection, reaction is concentrated The amount was crystallized at least, and 63.3 g of a white powder was obtained by filtration, yield 95%. The HPLC detection content is greater than 98%. Example 4: Preparation of 1,2,3-tri-O-acetyl-5-deoxy-D-ribose
20g 2、 3 -二 _0_乙酰基 _5 -脱氧 -肌苷加入到 50ml ~ 120ml醋酐中。 再加 入 5ml ~ 10ml醋酸.加热溶解后加入 3-5g 732树脂, 加热回流 4~ 8小时, TCL检测反应结束, 过滤, 用醋酸酐漂洗 2遍滤渣, 收集滤液浓缩至干, 加 甲醇水溶液溶解、 结晶、 分离, 得白色晶体 12.5g收率为 80%。 熔点: 66~ 67 °C; MS- EI m/z: 261 [M+H]+。 元素分析: C11H1607, 计算值(% ): C 50.77, H 6.15; 实测值 ( % ): C 50.68, H 6.03。 'H-NMR ( 300MHz, CDC13 ) δ 1.36-1.38 (3H, -CH3) , 2.06-2.12 (9H, C0CH3) , 4.25-4.29 (1H, 糖上 5位 氢), 5.08-5.33 (2H, 糖上 3和 4为氢), 6.11(1H, 糖上 2位氢)。 已经根据优选实施例对本发明作了描述。 应当理解的是前面的描述和 实施例仅仅为了举例说明本发明而已。 在不偏离本发明的精神和范围的前 提下, 本领域技术人员可以设计出本发明的多种替换方案和改进方案, 其 均应被理解为在本发明的保护范围之内。 20g 2, 3 - 2-0-acetyl-5-deoxy-inosine is added to 50 ml ~ 120 ml of acetic anhydride. Add 5ml ~ 10ml acetic acid. Add 3-5g 732 resin after heating and dissolve, heat and reflux for 4~8 hours, TCL detection reaction is finished, filter, rinse the filter residue with acetic anhydride for 2 times, collect the filtrate to dryness, add The aqueous methanol solution was dissolved, crystallized, and separated to obtain a white crystal of 12.5 g in a yield of 80%. Melting point: 66~ 67 °C; MS- EI m/z: 261 [M+H]+. Elemental analysis: C11H1607, calculated (%): C 50.77, H 6.15; Found (%): C 50.68, H 6.03. 'H-NMR (300MHz, CDC1 3 ) δ 1.36-1.38 (3H, -CH 3 ) , 2.06-2.12 (9H, C0CH 3 ) , 4.25-4.29 (1H, 5-position hydrogen on sugar), 5.08-5.33 (2H , 3 and 4 on the sugar are hydrogen), 6.11 (1H, 2 hydrogen on the sugar). The invention has been described in terms of a preferred embodiment. It is to be understood that the foregoing description and embodiments are merely illustrative of the invention. Numerous alternatives and modifications of the invention may be devised by those skilled in the art without departing from the spirit and scope of the invention.

Claims

权利要求书 Claim
1、 式 I所示 5-脱氧 -D-核糖的合成方法,其特征在于由式 V的肌苷为原料, 经如下步骤得到式 I化合物:  A method for synthesizing 5-deoxy-D-ribose represented by Formula I, characterized in that the inosine of the formula V is used as a raw material, and the compound of the formula I is obtained by the following steps:
( 1 ) 肌苷的糖 5位上的羟亚甲基转化为甲基, 制得式 III的 5-脱氧肌苷  (1) The hydroxymethylene group at the 5-position of the inosine is converted to a methyl group to prepare 5-deoxyinosine of the formula III.
Figure imgf000011_0001
Figure imgf000011_0001
V III  V III
( 2 ) 5-脱氧肌
Figure imgf000011_0002
(2) 5-deoxygen
Figure imgf000011_0002
Figure imgf000011_0003
Figure imgf000011_0003
III 其中, Ri、 R2、 R3相同或者不同, 各自独立地为羟基保护基, 优选 Ri、 R2、 R3相同, 均为乙酰基。 III wherein, Ri, R 2, R 3 the same or different, 2, R is independently the same as a hydroxy protecting group, preferably Ri, R 3, are an acetyl group.
2、 根据权利要求 1 所述的方法, 其中, 所述的步骤(1 ) 中, 肌苷经卤代 反应形成式 IV的 5-卤代 -5-脱氧肌苷, 再经氢化反应制得式 III 的 5- 脱氧肌苷 2. The method according to claim 1, wherein in the step (1), the inosine is halogenated to form a 5-halo-5-deoxyinosine of the formula IV, and then hydrogenated to obtain a formula. 5-deoxyinosine III
Figure imgf000011_0004
Figure imgf000011_0004
V IV III 其中, 所述的 X为卤原子, 优选为碘。 V IV III Wherein X is a halogen atom, preferably iodine.
3、 根据权利要求 1或 2所述的方法, 其中, 所述的步骤(2 ) 中, 5-脱氧 肌苷糖上的羟基经保护后形成式 I I 的 5-脱氧肌苷, 再脱糖苷基和保护 羟基, 制得式 I的 5-脱氧 -D-核糖 The method according to claim 1 or 2, wherein in the step (2), the hydroxyl group on the 5-deoxyinosine saccharide is protected to form 5-deoxyinosine of the formula II, and then a deglycosyl group. And protecting the hydroxyl group to produce 5-deoxy-D-ribose of formula I
Figure imgf000012_0001
Figure imgf000012_0001
II I 其中, Ri、 R2、 R3相同或者不同, 各自独立地为羟基保护基, 优选 Ri、 R2、 R3相同, 均为乙酰基。 II I wherein Ri, R 2 and R 3 are the same or different, and each independently is a hydroxy protecting group, and preferably Ri, R 2 and R 3 are the same, and all are acetyl groups.
4、 根据权利要求 3所述的方法, 其特征在于, 由式 V的肌苷为原料, 经包 含如下步骤的方法制得式 l a 所示的 1 , 2, 3-三 -0-乙酰基 -5-脱氧 -D-核 糖:  The method according to claim 3, wherein the inosine of the formula V is used as a raw material, and the 1, 2, 3-tri-O-acetyl group represented by the formula la is obtained by a method comprising the following steps: 5-deoxy-D-ribose:
( 1 ) 在有机溶剂中式 V的肌苷与碘反应制得式 IVa的 5-碘代 -5-脱氧肌苷  (1) 5-inodo-5-deoxyinosine of formula IVa is prepared by reacting inosine of formula V with iodine in an organic solvent.
Figure imgf000012_0002
制得式 III的 5-脱氧肌苷
Figure imgf000012_0002
Preparation of 5-deoxyinosine of formula III
( 3) 在有机溶剂中式 III的 5-脱氧肌苷与醋酐反应制得式 Ila的 2, 3-二 -0-乙酰基 -5-脱氧肌苷 (3) The 5-deoxyinosine of the formula III is reacted with acetic anhydride in an organic solvent to prepare 2,3-di-O-acetyl-5-deoxyinosine of the formula Ila.
Figure imgf000013_0001
Figure imgf000013_0001
III Ila 其中, Ac表示乙酰基;  III Ila wherein, Ac represents an acetyl group;
(4) 在醋酐和醋酸的混合溶剂中, 在强酸性阳离子树脂作用下式 Ila 的 2, 3-二 -0-乙酰基 -5-脱氧肌苷断键脱糖苷制得式 la的 1, 2, 3-三 -0-乙 酰基 -5-脱氧 -D-核糖 (4) In a mixed solvent of acetic anhydride and acetic acid, 2, 3-di-0-acetyl-5-deoxyinosine of the formula Ila is deactivated by a strong acidic cationic resin to obtain a formula 1 of 2, 3-Tri-0-acetyl-5-deoxy-D-ribose
Figure imgf000013_0002
Figure imgf000013_0002
Ila la 其中, AC表示乙酰基。  Ila la wherein AC represents an acetyl group.
、 根据权利要求 4所述的方法, 其中所述的步骤(1 ) 中, 式 V的肌苷是 在 DMF中, 在咪唑和三苯基膦催化剂存在下, 于 80-120°C条件下与碘反 应 4~6小时生成式 IVa的 5-碘代 -5-脱氧肌苷, 其中, 肌苷与咪唑、 肌 苷与三苯基膦和肌苷与碘的质量比依次为 1: 0.8~1.4、 1: 1 ~1.4和 1: 0.9 ~ 1.4。 The method according to claim 4, wherein in the step (1), the inosine of the formula V is in DMF, in the presence of an imidazole and a triphenylphosphine catalyst, at 80-120 ° C. 5-iodo-5-deoxyinosine of formula IVa is formed by iodine reaction for 4-6 hours, wherein the mass ratio of inosine to imidazole, inosine and triphenylphosphine and inosine and iodine are 1: 0.8~1.4 1, 1: ~ 1.4 and 1: 0.9 ~ 1.4.
、 根据权利要求 4所述的方法, 其中所述的步骤(2) 中, 式 IVa的 5-碘 代 -5-脱氧肌苷在甲醇中, 以镍为催化剂, 在三乙胺存在条件下与氢气反 应生成式 III的 5-脱氧肌苷, 其中, 镍用量为式 IVa的 5-碘代 -5-脱氧 肌苷的 30~50%。 The method according to claim 4, wherein in the step (2), 5-iodine of the formula IVa Dehydro-5-deoxyinosine is reacted with hydrogen in methanol in the presence of triethylamine to form 5-deoxyinosine of formula III, wherein the amount of nickel is 5-iodo-5 of formula IVa. - 30 to 50% of deoxyinosine.
、 根据权利要求 4所述的方法, 其中所述的步骤(3) 中, 式 III的 5-脱 氧肌苷是在二氯甲烷中, 在三乙胺存在条件下与醋酐于 40~50°C反应The method according to claim 4, wherein in the step (3), the 5-deoxyinosine of the formula III is in methylene chloride in the presence of triethylamine at 40 to 50 ° with acetic anhydride. C reaction
1 ~ 3小时生成式 Ila的 2, 3-二 -0-乙酰基 -5-脱氧肌苷。 2, 3-di-O-acetyl-5-deoxyinosine of formula Ila is formed in 1 to 3 hours.
、 根据权利要求 4所述的方法, 其中所述的步骤(4) 中, 式 Ila的 2,3- 二 -0-乙酰基 -5-脱氧肌苷加到醋酐和醋酸的混合溶剂中, 再加入强酸性 阳离子树脂加热回流 4~8小时生成式 la的 1, 2, 3-三 -0-乙酰基 -5-脱 氧 -D-核糖。 The method according to claim 4, wherein in the step (4), 2,3-di-0-acetyl-5-deoxyinosine of the formula Ila is added to a mixed solvent of acetic anhydride and acetic acid, Further, a strong acid cation resin is added and heated under reflux for 4 to 8 hours to form 1,2,3-tris--0-acetyl-5-deoxy-D-ribose of the formula la.
PCT/CN2008/070190 2007-01-30 2008-01-25 Method for synthesizing 1,2,3-tri-o-acetyl-5-deoxy-d-ribose WO2008092405A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2007100198737A CN100432088C (en) 2007-01-30 2007-01-30 Method of synthesizing 1,2,3-tri-O-acetyl-5-deoxidation-D-ribose
CN200710019873.7 2007-01-30

Publications (1)

Publication Number Publication Date
WO2008092405A1 true WO2008092405A1 (en) 2008-08-07

Family

ID=38699993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/070190 WO2008092405A1 (en) 2007-01-30 2008-01-25 Method for synthesizing 1,2,3-tri-o-acetyl-5-deoxy-d-ribose

Country Status (2)

Country Link
CN (1) CN100432088C (en)
WO (1) WO2008092405A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260298A (en) * 2010-05-24 2011-11-30 重庆福安药业(集团)股份有限公司 Method for synthesizing 1,2,3-O-triacetyl-5-deoxy-bata-D-ribose

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100432088C (en) * 2007-01-30 2008-11-12 合肥巨林医药科技有限公司 Method of synthesizing 1,2,3-tri-O-acetyl-5-deoxidation-D-ribose
CN101918422A (en) 2007-10-05 2010-12-15 株式会社Api Process for production of ribofuranose derivatives
CN101993463A (en) * 2009-08-19 2011-03-30 成都康弘药业集团股份有限公司 Preparation method of capecitabine and intermediate thereof
CN102432642B (en) * 2011-10-17 2014-07-23 江西科技师范大学 Synthesis method of 1,2,3-O-triacetyl-5-deoxy-D-ribofuranose
CN103772450A (en) * 2012-10-18 2014-05-07 黑龙江福和华星制药集团股份有限公司 1, 2, 3-triacetyl-5-deoxy-D-ribose preparation method
CN103897005B (en) * 2012-12-27 2017-07-28 鲁南制药集团股份有限公司 A kind of method for operating continuously synthesis capecitabine
CN104650160A (en) * 2015-01-13 2015-05-27 济南大学 Novel synthesis method of capecitabine key intermediate 1,2,3-O-triacetyl-5-deoxy-D-ribose
CN107118241A (en) * 2017-05-03 2017-09-01 南京信息工程大学 A kind of preparation method of 6 nitro deoxidation triacetyl methyl glucoside
CN107827938B (en) * 2017-10-27 2020-08-07 新乡拓新药业股份有限公司 Preparation method of 1,2, 3-tri-O-acetyl-5-deoxy- β -D-ribose
CN108484690B (en) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 Preparation method of 1,2, 3-tri-O-acetyl-5-deoxy-beta-D-ribose
CN108727440B (en) * 2018-05-16 2021-12-17 新乡拓新药业股份有限公司 Preparation method of 1,2, 3-tri-O-acetyl-5-deoxy-beta-D-ribose

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101012252A (en) * 2007-01-30 2007-08-08 王成举 Method of synthesizing 1,2,3-tri-O-acetyl-5-deoxidation-D-ribose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101012252A (en) * 2007-01-30 2007-08-08 王成举 Method of synthesizing 1,2,3-tri-O-acetyl-5-deoxidation-D-ribose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAKULSKI Z. ET AL.: "An efficient synthesis of 5-deoxy-D-ribohexose", POLISH JOURNAL OF CHEMISTRY, vol. 69, no. 6, 1995, pages 912 - 917 *
SAIRAM P. ET AL.: "Synthesis of 1,2,3-tri-O-acetyl-5-deoxy-D-ribofuranose from D-ribose", CARBOHYDRATE RESEARCH, vol. 338, no. 4, 2003, pages 303 - 306, XP004404435, DOI: doi:10.1016/S0008-6215(02)00464-0 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260298A (en) * 2010-05-24 2011-11-30 重庆福安药业(集团)股份有限公司 Method for synthesizing 1,2,3-O-triacetyl-5-deoxy-bata-D-ribose

Also Published As

Publication number Publication date
CN100432088C (en) 2008-11-12
CN101012252A (en) 2007-08-08

Similar Documents

Publication Publication Date Title
WO2008092405A1 (en) Method for synthesizing 1,2,3-tri-o-acetyl-5-deoxy-d-ribose
CN102766098B (en) Prepare method and the intermediate of integrase inhibitor
JPS62149695A (en) Selective methylation of erythromycin a derivative
CN103570696B (en) A kind of preparation method of Axitinib intermediate and preparing the application in Axitinib
WO2008144980A1 (en) The preparation method and intermediates of capecitabine
CN111470998A (en) Intermediate for synthesizing camptothecin derivative and preparation method and application thereof
CN105330581A (en) Preparation method for (S)-oxiracetam
CN105330582A (en) Preparation method for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide
CN113200951B (en) Synthesis method of 2-nitrosugar alkene
WO2009094847A1 (en) A capecitabine hydroxyl-derivative, its preparation processes and uses for preparing capecitabine
CN109503693B (en) Process for synthesizing Aramchol by using cholic acid as raw material
CN113683651A (en) Preparation method of GalNAc intermediate
WO2013123896A1 (en) Method for preparing 3-o-benzyl-1,2-o-isopropylidene-α-l-furan idose
CN115697968B (en) Preparation method of (S) -2-amino-3- (4- (2, 3-dimethylpyridine-4-yl) phenylpropionic acid methyl ester and salt thereof
WO2022106547A1 (en) Process for synthesising a ror gamma inhibitor
WO2016145997A1 (en) Pharmaceutically active sugar molecule and synthesis method thereof
CN110981933A (en) Method for efficiently synthesizing Aramchol
JPH03209393A (en) Synthesis of 1-(3-azide-2, 3-dideoxy-beta- d-erythropentfuranosil) thymine and its related compound
CN108409561B (en) Preparation method of 5-aminolevulinic acid hydrochloride and intermediate
JPH058200B2 (en)
EP1539751B1 (en) Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides
CN114605320B (en) Synthesis method of 5-nitro-6-methylnicotinic acid ethyl ester
JP3511788B2 (en) 7-Amino-2,3-dihydro-2-oxo-pyrido [2,3-d] pyrimidine and method for producing the same
JP2001525843A (en) Method for producing deoxyuridine derivative
CN113072585B (en) Preparation of chiral aryl phosphonic acid cyclic diester and derivative thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08706567

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING LOSS OF RIGHTS PURSUANT TO RULE112(1) EPC DATED 14.01.2010.

122 Ep: pct application non-entry in european phase

Ref document number: 08706567

Country of ref document: EP

Kind code of ref document: A1